299 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
ALKS Alkermes plc $38.61 $6B N/A
Article Searches
Zealand Initiates Second Late-Stage CHI Study on Dasiglucagon http://www.zacks.com/stock/news/655740/zealand-initiates-second-late-stage-chi-study-on-dasiglucagon?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-655740 Dec 05, 2019 - Zealand (ZEAL) announces initiation of the second phase III study to evaluate dasiglucagon in pediatric patients with congenital hyperinsulinism.
Amarin's Vascepa MAA for Heart Risk Indication Accepted in EU http://www.zacks.com/stock/news/652438/amarins-vascepa-maa-for-heart-risk-indication-accepted-in-eu?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-652438 Dec 03, 2019 - The EMA validates Amarin's (AMRN) regulatory application seeking approval for Vascepa as a treatment to reduce risk of cardiovascular events.
ChemoCentryx Up on Encouraging Rare Disease Candidate Data http://www.zacks.com/stock/news/643135/chemocentryx-up-on-encouraging-rare-disease-candidate-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-643135 Nov 27, 2019 - ChemoCentryx (CCXI) announces positive data pivotal study evaluating its lead candidate, avacopan, in patients with ANCA vasculitis, a rare disease affecting small blood vessels.
Are Investors Undervaluing Alaska Air Group (ALK) Right Now? http://www.zacks.com/stock/news/640764/are-investors-undervaluing-alaska-air-group-alk-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_2-640764 Nov 26, 2019 - Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
What Makes Alaska Air (ALK) a New Buy Stock http://www.zacks.com/stock/news/641015/what-makes-alaska-air-alk-a-new-buy-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-641015 Nov 26, 2019 - Alaska Air (ALK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Intercept's (ICPT) NDA for NASH Drug Gets Priority Review http://www.zacks.com/stock/news/638430/intercepts-icpt-nda-for-nash-drug-gets-priority-review?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-638430 Nov 26, 2019 - Intercept (ICPT) obtains Priority Review for its NDA for OCA in the United States for the treatment of fibrosis due to NASH.
Alexion Gets Approval for Label Expansion of Soliris in Japan http://www.zacks.com/stock/news/636828/alexion-gets-approval-for-label-expansion-of-soliris-in-japan?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-636828 Nov 25, 2019 - Alexion (ALXN) gets Japan Ministry of Health, Labour and Welfare's approval for the label expansion of Soliris.
Biogen Ends Enrollment in Eye Disorder Study on Gene Therapy http://www.zacks.com/stock/news/632831/biogen-ends-enrollment-in-eye-disorder-study-on-gene-therapy?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-632831 Nov 22, 2019 - Biogen (BIIB) completes enrollment in the global phase III STAR clinical study evaluating the gene therapy timrepigene emparvovec for the treatment of a rare, inherited retinal disorder.
Vertex (VRTX) Gets French Reimbursement for CF Drug Orkambi http://www.zacks.com/stock/news/631140/vertex-vrtx-gets-french-reimbursement-for-cf-drug-orkambi?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-631140 Nov 21, 2019 - The French reimbursement for Vertex's (VRTX) cystic fibrosis medicine Orkambi removes a key overhang for the stock.
Alnylam's Givosiran Gets FDA Nod for Acute Hepatic Porphyria http://www.zacks.com/stock/news/631074/alnylams-givosiran-gets-fda-nod-for-acute-hepatic-porphyria?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-631074 Nov 21, 2019 - Alnylam (ALNY) gets FDA approval for givosiran injection, to be marketed by the trade name of Givlaari, for the treatment of adults with AHP.

Pages: 123456...30

Page 1>